




(86) Date de dépôt PCT/PCT Filing Date: 2005/08/22
(87) Date publication PCT/PCT Publication Date: 2006/03/02
(85) Entrée phase nationale/National Entry: 2007/02/06
(86) N° demande PCT/PCT Application No.: US 2005/029862
(87) N° publication PCT/PCT Publication No.: 2006/023883
(30) Priorité/Priority: 2004/08/20 (US60/603,168)

(51) Cl.Int./Int.Cl. *C07C 211/03* (2006.01)
(71) Demandeur/Applicant:
UNIVERSITY OF VIRGINIA PATENT FOUNDATION, US
(72) Inventeurs/Inventors:
GRAY, LLOYD S., US;
MACDONALD, TIMOTHY L., US;
HAVERSTICK, DORIS M., US;
PATTERSON, JACLYN R., US;
MCCALMONT, WILLIAM F., US
(74) Agent: MCFADDEN, FINCHAM

(54) Titre : INHIBITEURS DE CANAL CALCIUM DE TYPE T
(54) Title: T TYPE CALCIUM CHANNEL INHIBITORS



(57) **Abrégé/Abstract:**

The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wherein R₁ is C₁-C₄ alkyl, hydroxy, or C₁-C₄ alkoxy; Z is NH, NCH₃, O, S, or CH₂; Y is NH, O, or CH₂ with the proviso that Y and Z are not the same; R₂ is H, halo, NH₂, C₁-C₄ alkyl, hydroxy, or C₁-C₄ alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m + n = an integer ranging from 2-9; and R₃ is H, halo, NH₂, C₁-C₄ alkyl, hydroxy, or C₁-C₄ alkoxy.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 March 2006 (02.03.2006)

PCT

(10) International Publication Number
WO 2006/023883 A3

(51) International Patent Classification:
C07C 211/03 (2006.01)

(21) International Application Number:
PCT/US2005/029862

(22) International Filing Date: 22 August 2005 (22.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/603,168 20 August 2004 (20.08.2004) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF VIRGINIA PATENT FOUNDATION** [US/US]; 1224 West Main Street, Suite 1-110, Charlottesville, Virginia 22903 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GRAY, Lloyd S.** [US/US]; 2955 Cove Trace, Charlottesville, VA 22911 (US). **MACDONALD, Timothy L.** [US/US]; 2 Ivy Depot Lane, Ivy, VA 22945 (US). **HAVERSTICK, Doris M.** [US/US]; 56 Hickory Lane, Charlottesville, VA 22911 (US). **PATTERSON, Jaclyn R.** [US/US]; 291 Poplar Avenue, Apt Q596, Devon, PA 19333 (US). **MCCALMONT, William F.** [US/US]; 46 Lilac Road, Ruckersville, VA 22968 (US).

(74) Agent: **GROLZ, Edward W.**; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, NY 11530 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
27 July 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: T TYPE CALCIUM CHANNEL INHIBITORS



(I)

(57) Abstract: The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wherein R₁ is C₁-C₄ alkyl, hydroxy, or C₁-C₄ alkoxy; Z is NH, NCH₃, O, S, or CH₂; Y is NH, O, or CH₂ with the proviso that Y and Z are not the same; R₂ is H, halo, NH₂, C₁-C₄ alkyl, hydroxy, or C₁-C₄ alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m + n = an integer ranging from 2-9; and R₃ is H, halo, NH₂, C₁-C₄ alkyl, hydroxy, or C₁-C₄ alkoxy.

T TYPE CALCIUM CHANNEL INHIBITORS

BACKGROUND OF THE INVENTION

Influx of extracellular calcium is critical for a number of vital cellular processes. Calcium influx is generally mediated by calcium channels, which are grouped into several families one of which is the T type calcium channel family. Pharmacological modulation of the T type calcium channel's function is tremendously important in the practice of medicine; for example, T type calcium channel inhibitors are in widespread use in the treatment of neurological diseases (e.g. epilepsy, petit mal seizure, absence seizure, neuropathic pain, and etc.) and cardiovascular diseases (e.g. hypertension, unstable angina, and etc.). For example, mibefradil, a T type calcium inhibitor, was clinically efficacious in treating hypertension and cardiac arrhythmia. Studies also suggest that T-type calcium channels may play an important role in age related macular degeneration. Recently, we have showed that the $\alpha 1H$ and $\delta 25$ isoforms of T type calcium channels are present in cancer cell lines and that novel chemical agents could be synthesized to block calcium entry via this channel thus inhibiting cancer cell proliferation.

Ca^{2+} entry is critical for cellular proliferation. Because unusually rapid proliferation is a hallmark of cancer, elucidation of the mechanism of Ca^{2+} entry is of scientific importance with potential clinical significance. However, the mechanism or mechanisms of Ca^{2+} entry in electrically non-excitable cells, which constitute most types of cancer, remain elusive. The majority of cancers arise from cell types considered "electrically non-excitable." This is to distinguish the means of regulation of Ca^{2+} entry in these cells from those having action potentials, that is "electrically excitable" cells. In electrically excitable cells, an action potential opens voltage gated Ca^{2+} channels that admit the Ca^{2+} required for initiating events such as neurosecretion. In electrically non-excitable cells, the regulatory mechanism activating Ca^{2+} entry is unclear in part because of the uncertainty about the molecular mechanism by which Ca^{2+} entry occurs.

The two types of ion channels or transporters most commonly implicated in capacitative Ca^{2+} entry are I_{CRAC} and members of the Trp. These two

channel types do not share many properties other than relative selectivity for Ca^{2+} , albeit sometimes very weak, and lack of voltage dependent gating. It has been difficult, however, to tie these proteins' function to capacitative Ca^{2+} entry. This may reflect a particular complexity of Ca^{2+} signaling in electrically non-excitable cells arising from participation of numerous channels and transporters in this process. It is also possible that the primary means of Ca^{2+} entry in electrically non-excitable cells has yet to be fully elucidated.


We have taken an alternative approach to dissecting the Ca^{2+} entry pathway in electrically non-excitable cells. We first took advantage of Ca^{2+} entry blockade by Ni^{2+} , as measured by fluorescence techniques (Merritt, J.E. and Rink, T.J. 1987. Regulation of cytosolic free calcium in fura-2-loaded rat parotid acinar cells. *J. Biol. Chem.* 262:17362-17369; Merritt, J.E., Jacob, R., and Hallam, T.J. 1989. Use of manganese to discriminate between calcium influx and mobilization from internal stores in stimulated human neutrophils. *J. Biol. Chem.* 264:1522-1527; Skryma, R., Mariot, P., Bourhis, X.L., Coppenolle, F.V., Shuba, Y., Abeele, F.V., Legrand, G., Humez, S., Boilly, B., and Prevarskaya, N. 2000. Store depletion and store-operated Ca^{2+} current in human prostate cancer LNCaP cells: involvement in apoptosis. *J. Physiol. (Lond.)* 527 Pt 1:71-83), to identify compounds in the published literature with a similar ability. The structure/activity relationship of these known compounds was used to guide the synthesis of novel compounds with enhanced potency to block Ca^{2+} entry into and proliferation of several cancer cell lines. Administration of one of these compounds, TH-1177, significantly extended the lifespan of nude mice inoculated with human PC3 prostate cancer cells (Haverstick, D.M., Heady, T.N., Macdonald, T.L., and Gray, L.S. 2000. Inhibition of human prostate cancer proliferation *in vitro* and in a mouse model by a compound synthesized to block Ca^{2+} entry. *Cancer Res* 60:1002-1008). We show here that two representative compounds block the Ca^{2+} current through the heterologously expressed $\alpha 1\text{H}$ isoform of T type Ca^{2+} channels and inhibit proliferation of HEK293 cells stably transfected with this isoform. These two compounds blocked the Ca^{2+} current and capacitative Ca^{2+} entry with similar potencies and identical stereoselectivity. Importantly, cell lines sensitive

to our novel compounds express message for $\alpha 1H$, its $\delta 25$ splice variant, or both while a cell line resistant to our compounds does not detectably express either message.

The library of compounds we have developed has apparently broad activity against cancer cell lines from various tissues. They act cytostatically and are
 5 equally potent at inhibiting hormone sensitive and insensitive breast and prostate cancer lines. We demonstrate here the likely target of their anti-proliferative activity. Taken together, these observations raise the possibility of directed chemical synthesis of compounds that inhibit Ca^{2+} entry into and thereby proliferation of cancer cells.

10 SUMMARY OF THE INVENTION

Accordingly, the present invention provides a method for the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug
 15 thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug. Preferably, the T type calcium channel inhibitor has a structure represented by Formula (I):



Formula(I),

wherein

R_1 is C_1 - C_4 alkyl, hydroxy, or C_1 - C_4 alkoxy;

20 Z is NH , NCH_3 , O , S , or CH_2 ;

Y is NH , O , or CH_2 with the proviso that Y and Z are not the same;

R_2 is H , halo, NH_2 , C_1 - C_4 alkyl, hydroxy, or C_1 - C_4 alkoxy;

m and n are independently selected from integers ranging from 1-5 with the proviso that $m + n =$ an integer ranging from 2-9; and


25 R_3 is H , halo, NH_2 , C_1 - C_4 alkyl, hydroxy, or C_1 - C_4 alkoxy.

More preferably, R_1 is hydroxy or C_1 - C_4 alkoxy; Z is N or O ; R_2 is H , halo, NH_2 or

hydroxy; and R_3 is H. The disease or condition is preferably selected from the group consisting of unstable angina, hypertension, epilepsy, neuropathic pain, petit mal seizure, absence seizure, age related macular degeneration, cancer, and pre-cancerous condition.

5 The present invention also provides a method for reducing proliferation of electrically non-excitabile cells, which comprises administering a T type calcium channel inhibitor of formula (I) as described above.

In another aspect, the present invention provides a compound of Formula (I)



Formula(I),

wherein

R_1 is C_1 - C_4 alkyl, hydroxy, or C_1 - C_4 alkoxy;

Z is NH, NCH_3 , O, S, or CH_2 ;

Y is NH, O, or CH_2 with the proviso that Y and Z are not the same;


15 R_2 is H, halo, NH_2 , C_1 - C_4 alkyl, hydroxy, or C_1 - C_4 alkoxy;


m and n are independently selected from integers ranging from 1-5 with the proviso that $m + n =$ an integer ranging from 2-9; and

R_3 is H, halo, NH_2 , C_1 - C_4 alkyl, hydroxy, or C_1 - C_4 alkoxy;

or a pharmaceutically acceptable salt thereof.

20 Preferably, R_1 is hydroxy or C_1 - C_4 alkoxy; Z is N or O; R_2 is H, halo, NH_2 or hydroxy; and R_3 is H. More preferably, the compound of formula (I) is selected from the group consisting of the following compounds:





In another aspect, the present invention provides a pharmaceutical
 5 composition comprising a therapeutically effective amount of a compound of formula (I) as described above, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.

In another aspect, the present invention provides a method for the
 10 treatment of cancer or pre-cancerous condition in a mammal, which comprises administering to the mammal a therapeutically effective amount of a compound of formula (I) as described above, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug in combination with one or more anti-tumor agent.

The present application also provides pharmaceutical combination
 15 composition comprising a therapeutically effective amount of a combination of a compound of formula (I) as described above, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug; and one or more anti-tumor agent.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Identification of known compounds that block Ca^{2+} entry and proliferation and design of novel compounds with increased potency.

Proliferation and Ca^{2+} entry were determined in Jurkat cancer cells as described
5 below in the Materials and Methods. Individual concentration-response curves for each activity and compound were constructed and IC_{50} values were calculated. The calculated least squares regression is shown as a solid line and a line with a slope of one is shown as a dashed line. Panel A: Using Ni^{2+} sensitivity as a guide, known compounds were identified that block Ca^{2+} entry and proliferation in Jurkat cells.
10 Panel B: An SAR was developed from the data depicted in panel A leading to the synthesis of novel compounds that block Ca^{2+} entry and proliferation in Jurkat cells.

Figure 2. The Ca^{2+} ionophore ionomycin overcomes the inhibition of Ca^{2+} entry into and proliferation of Jurkat cells produced by TH-1177. Panel A. Ca^{2+} entry into Jurkat cells was determined as described in Materials and Methods.

15 Ionomycin at the indicated concentrations was added 30 s and the mitogenic monoclonal antibody OKT3 was added at a concentration of 1 $\mu\text{g}/\text{ml}$ at 60 s. Either EGTA at 2.5 mM or TH-1177 at the indicated concentrations was added at 150 s. The percentage inhibition was determined as described in Materials and Methods. Panel B. Jurkat cells were grown for 48 hrs in the presence (open symbols) or absence (closed
20 symbols) of 30 nM ionomycin and the indicated concentrations of TH-1177. Percent control growth was determined as described in Materials and Methods.

Figure 3. Amplicons of two sizes were identified in Jurkat and SK-N-SF cancer cell lines using $\alpha 1\text{H}$ Ca^{2+} channel specific PCR primers. Messenger RNA was extracted and amplified as described in Materials and Methods using the
25 primers described previously (Mariot, P., Vanoverberghe, K., Lalevee, N., Rossier, M.F., and Prevarskaya, N. 2002. Overexpression of an $\alpha 1\text{H}$ (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. *J Biol. Chem* 277:10824-10833). The resulting products were isolated by gel electrophoresis and visualized by ethidium bromide staining and visualized by UV
30 illumination.

Figure 4. The sequences of the amplicons shown in Figure 4 are virtually identical to either $\alpha 1H$ or its $\delta 25$ splice variant. The amplicons shown in Figure 4 were sequenced as described in Materials and Methods. The GenBank database was then queried and the alignments shown were obtained.

5 Figure 5. Blockade of the $\alpha 1H$ Ca^{2+} current by the known T type Ca^{2+} channel mibefradil or TH-1177 inhibits proliferation of stably transfected HEK293 cells. HEK293 cells were stably transfected the $\alpha 1H$ gene as described in Materials and Methods. Proliferation and the Ca^{2+} current were determined as described in Materials and Methods.

10 Figure 6. TH-1177 and TH-1211 are stereoisomers about one of two chiral centers and have different potencies at inhibiting the proliferation of PC3 prostate cancer cells. Panel A: The structures of TH-1177 and TH-1211 were determined as described in Materials and Methods. The diastereomers are racemic at the benzhydrol center (solid arrows) and enantiomeric at the proline center (open
15 arrows) with TH-1177 having the S configuration and TH-1211 having the R. Panel B: The proliferation of PC3 human prostate cancer cells was determined as described in Materials and Methods. The IC_{50} for TH-1177 was 14 μM (open boxes) and for TH-1211 was 42 μM (inverted triangles).

 Figure 7. TH-1177 and TH-1211 have different potencies at inhibiting
20 the Ca^{2+} current through transfected $\alpha 1H$ channels. The current carried by transfected $\alpha 1H$ Ca^{2+} channels was determined as described in Materials and Methods. The concentration response for TH-1177 and TH-1211 is shown in Fig. 6D. The IC_{50} for TH-1177 was 0.8 μM and for TH-1211 was 7 μM .

25 **Definitions**

 In describing and claiming the invention, the following terminology will be used in accordance with the definitions set forth below.

 As used herein, the term "purified" and like terms relate to an enrichment of a molecule or compound relative to other components normally
30 associated with the molecule or compound in a native environment. The term

"purified" does not necessarily indicate that complete purity of the particular molecule has been achieved during the process. A "highly purified" compound as used herein refers to a compound that is greater than 90% pure.

As used herein, the term "treating", "treat" or "treatment" includes
5 administering therapy to prevent, cure, or alleviate/prevent the symptoms associated with, a specific disorder, disease, injury or condition. For example treating cancer includes inhibition or complete growth arrest of a tumor, reduction in the number of tumor cells, reduction in tumor size, inhibition of tumor cell infiltration into peripheral organs/tissues, inhibition of metastasis as well as relief, to some extent, of
10 one or more symptoms associated with the disorder. The treatment of cancer also includes the administration of a therapeutic agent that directly decreases the pathology of tumor cells, or renders the tumor cells more susceptible to treatment by other therapeutic agents, e.g., radiation and/or chemotherapy. As used herein, the term "treating" includes prophylaxis of the specific disorder or condition, or alleviation of
15 the symptoms associated with a specific disorder or condition and/or preventing or eliminating said symptoms.

As used herein, the term "pharmaceutically acceptable carrier, vehicle or diluent" includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions such as an oil/water or water/oil emulsion,
20 and various types of wetting agents. The term also encompasses any of the agents approved by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including humans.

The term "therapeutically effective amount" means an amount of a compound of the present invention that ameliorates, attenuates or eliminates a
25 particular disease or condition or prevents or delays the onset of a particular disease or condition.

By "mammal" it is meant to refer to all mammals, including, for example, primates such as humans and monkeys. Examples of other mammals included herein are rabbits, dogs, cats, cattle, goats, sheep and horses. Preferably, the
30 mammal is a female or male human.

The phrase "compound(s) of the present invention" or "compound(s) of Formula (I)" or the like, shall at all times be understood to include all active forms of such compounds, including, for example, the free form thereof, e.g., the free acid or base form, and also, all prodrugs, polymorphs, hydrates, solvates, tautomers, and the like, and all pharmaceutically acceptable salts, unless specifically stated otherwise. It will also be appreciated that suitable active metabolites of such compounds are within the scope of the present invention.

The expression "prodrug" refers to compounds that are drug precursors which following administration, release the drug *in vivo* via some chemical or physiological process (e.g., a prodrug on being brought to the physiological pH or through enzyme action is converted to the desired drug form).

The expression "pre-cancerous condition" refers to a growth that is not malignant but is likely to become so if not treated. A "pre-cancerous condition" is also known as "pre-malignant condition" by one of ordinary skill in the art.

As used herein the term "anti-tumor agent" relates to agents known in the art that have been demonstrated to have utility for treating neoplastic disease. For example, antitumor agents include, but are not limited to, antibodies, toxins, chemotherapeutics, enzymes, cytokines, radionuclides, photodynamic agents, and angiogenesis inhibitors. Toxins include ricin A chain, mutant *Pseudomonas* exotoxins, diphtheria toxoid, streptonigrin, boamycin, saporin, gelonin, and pokeweed antiviral protein. Chemotherapeutics include 5-fluorouracil (5-FU), daunorubicin, cisplatin, bleomycin, melphalan, taxol, tamoxifen, mitomycin-C, and methotrexate as well as any of the compounds described in US Patent No. 6,372,719 (the disclosure of which is incorporated herein by reference) as being chemotherapeutic agents. Radionuclides include radiometals. Photodynamic agents include porphyrins and their derivatives. Angiogenesis inhibitors are known in the art and include natural and synthetic biomolecules such as paclitaxel, O-(chloroacetyl-carbonyl) fumagillol ("TNP-470" or "AGM 1470"), thrombospondin-1, thrombospondin-2, angiostatin, human chondrocyte-derived inhibitor of angiogenesis ("hCHIAMP"), cartilage-derived angiogenic inhibitor, platelet factor-4, gro-beta, human interferon-inducible

protein 10 ("IP10"), interleukin 12, Ro 318220, tricyclodecan-9-yl xanthate ("D609"), irsogladine, 8,9- dihydroxy-7-methyl-benzo[b]quinolizinium bromide ("GPA 1734"), medroxyprogesterone, a combination of heparin and cortisone, glucosidase inhibitors, genistein, thalidomide, diamino-antraquinone, herbimycin, ursolic acid, and oleanolic acid. Anti-tumor therapy includes the administration of an anti-tumor agent or other therapy, such as radiation treatments, that has been reported as being useful for treating cancer.

As used herein, the term "halogen" or "halo" includes bromo, chloro, fluoro, and iodo.

The term "haloalkyl" as used herein refers to an alkyl radical bearing at least one halogen substituent, for example, chloromethyl, fluoroethyl or trifluoromethyl and the like.

The term " C_1 - C_n alkyl" wherein n is an integer, as used herein, represents a branched or linear alkyl group having from one to the specified number of carbon atoms. Typically C_1 - C_6 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and the like.

The term " C_2 - C_n alkenyl" wherein n is an integer, as used herein, represents an olefinically unsaturated branched or linear group having from 2 to the specified number of carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, 1-propenyl, 2-propenyl, 1,3-butadienyl, 1-butenyl, hexenyl, pentenyl, and the like.

The term " C_2 - C_n alkynyl" wherein n is an integer refers to an unsaturated branched or linear group having from 2 to the specified number of carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 1-pentylnyl, and the like.


The term " C_3 - C_n cycloalkyl" wherein n = 4-8, represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

As used herein, the term "optionally substituted" refers to from zero to four substituents, wherein the substituents are each independently selected. Each of

the independently selected substituents may be the same or different than other substituents.

As used herein the term "aryl" refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, benzyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, and the like. Substituted aryl includes aryl compounds having one or two C₁-C₆ alkyl, halo or amino substituents. The term (C₅-C₈ alkyl)aryl refers to any aryl group which is attached to the parent moiety via the alkyl group. The term "heterocyclic group" refers to a C₃-C₈ cycloalkyl group containing from one to three heteroatoms wherein the heteroatoms are selected from the group consisting of oxygen, sulfur, and nitrogen.

The term "bicyclic" represents either an unsaturated or saturated stable 7- to 12-membered bridged or fused bicyclic carbon ring. The bicyclic ring may be attached at any carbon atom which affords a stable structure. The term includes, but is not limited to, naphthyl, dicyclohexyl, dicyclohexenyl, and the like. Any ring structure drawn with one or more bonds extending from the center of the ring is intended to designate a series of compounds that have a bond(s) extending from one of the carbon atoms of the ring to another atom. For example, the structure:



designates a series of compounds including 2-thienyl or 3-thienyl groups that contain an R₇ substituent at one of the remaining ring carbon atoms.

The compounds of the present invention contain one or more asymmetric centers in the molecule. In accordance with the present invention a structure that does not designate the stereochemistry is to be understood as embracing all the various optical isomers, as well as racemic mixtures thereof.

The term "pharmaceutically acceptable salt" refers to salts which retain the biological effectiveness and properties of the compounds of the present invention and which are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.

It is understood to one skilled in the art that “T type calcium channel inhibitors” are also known as “T type calcium channel inhibitors”.

DETAILED DESCRIPTION OF THE INVENTION


5 Changes in the cytosolic concentration of calcium are a critical component of numerous cellular processes. The calcium necessary for these changes comes from the extracellular milieu via influx through calcium channels. Calcium channels are grouped into several families based upon sequence analysis, biophysical characteristics and pharmacological sensitivity. Among these is the T type calcium
10 channel family. These calcium channels have been implicated in regulation of blood pressure, cardiac rhythm, and cellular proliferation. However there has been only one pharmacological agent, mibefradil, that has been proven to be clinically effective because of inhibition of T channel function. Unfortunately, mibefradil was withdrawn from market due to adverse interactions with other drugs leaving this therapeutic
15 approach unavailable.

 One embodiment of the present invention is directed to a series of novel synthetic compounds that inhibit calcium entry via T type calcium channels while other members of this series activate calcium entry. Inhibitors of calcium entry will be useful for treating hypertension, cardiac arrhythmia and clinically deleterious
20 cellular proliferation while activators of calcium entry will be useful as cardiac stimulants and inducers of programmed cell death with the intent of reducing the burden of clinically unwanted cells such as cancer cells. Examples of these compounds are as follows:

25

Exhibit A

Presence of Oxygen Atom




	Jurkat		PC3		LNCaP		MDA-435		MDA-231		MDA-361	
Table 5.1	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+
Series 1												
3.1	4	10	11	NE	3.5	10	12	25	8	10	8	10
3.2	3	3	9	10	2	5	10.5	10	10	8	4	6
Series 2												
3.3	70	60	>100	NE	42	NE	>100	>100	100			
3.4	3.7	3	10	~15	5.5	15	10	15	4	~20	4	10

NE = no effect at highest concentration of drug tested, all values in micromolar


In all Figures, "prolif" indicates the IC₅₀ for inhibition of proliferation of the indicated cell lines while "Ca2+" is the IC₅₀ for inhibition of calcium entry. As can be seen in this Figure, the presence of an ether linkage has a profound effect of biological activity but only when the amine is proximal to it.

Presence of Nitrogen

Series 1



Series 2




	Junkat		PC3		LNCaP		MDA-435		MDA-231		MDA-361	
Table 5.2	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+
Series 1												
3.5	50	7	33	30	25	10	55	10	50	10	45	25
3.6	>100	>100	>100	NE	>100	NE	>100	NE	>100	NE	>100	NE
3.8	7.5	10	11.5	10	3.5	10	15.7	10	10.6	10	7.5	20
Series 2												
3.7	>100	10	NE	NE	>100	NE	NE	NE	>100	60	>100	NE
3.9	3.5	3	4	NE	1.6	3	12	10	11.7	10	4	5

NE = no effect at the highest concentration of drug tested, all values in micromolar

This Figure demonstrates that nitrogen in the hydrocarbon "tether" is required for biological activity.

Basicity of the Nitrogen




	Jurkat		PC3		LNCaP		MDA-435		MDA-231		MDA-361	
Table 5.3	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+
Series 1												
3.10	>300	NE	>1mM	NE	>1mM	NE	>1mM	NE	>1mM	NE	>70	NE
3.11	5.4	3.3	14	NE	3.3	NE	22	NE	11.6	20	8.5	10
Series 2												
3.14	>100	30	>100	NE	>100	30	NE	30	NE	30	NE	10
3.15	4	10	11	NE	3.5	10	12	25	8	10	8	10

NE = no effect at the highest concentration of drug tested, all values in micromolar

This Figure demonstrates that the basicity of the nitrogen contributes to the biological activity.

Steric Bulk Around the Nitrogen



Increasing steric bulk around the nitrogen

Increasing biological activity

Table 5.4	Jurkat	PC3		LNCaP		MDA-435		MDA-231		MDA-361		
Compound	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+
3.14	7.6	10	11.5	10	35	10	15.7	10	10.6	10	7.6	20
3.15	12	10	32	20	4	7	27	20	24	10	16	20
3.16	23	30	55	NE	33	10	50	NE	21	NE	8	NE

NE = no effect at the highest concentration of drug tested, all values in micromolar

From this Figure, it can be seen that steric bulk around the nitrogen decreases biological activity.

Location of the Nitrogen





Table 5.6	Nitrogen	Oxygen	Jurkat		PC3		LNCaP		MDA-435		MDA-231	
Compound	Position	Present	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+	prolif	Ca2+
3.17	1	no	>100	30	>100	NE	>100	30	NE	30	NE	30
3.1	2	no	4	10	11	NE	3.5	10	12	25	8	10
3.19	3	no	4	10	10	NE	3	10	11	10	6	10
3.3	4	no	70	60	>100	NE	42	NE	>100		>100	100
3.21	5	no	30	30	11	30	7	NE	9		15	30
3.22	6	no	13	3	9	NE	9	NE	40	NE	25	10
3.23	7	no	~30	NE	>100	NE	~100	NE	NE	NE	NE	NE

NE = no effect at the highest concentration of drug tested, all values in micromolar

This Figure shows that biological activity is affected by the position of the nitrogen along the hydrocarbon tether.

In accordance with one embodiment a novel compound that inhibit Ca^{2+} entry, and thereby proliferation of cancer cells is provided. The compounds have the general structure of Formula (I):



Formula(I),

wherein

R_1 is $\text{C}_1\text{-C}_4$ alkyl, hydroxy, or $\text{C}_1\text{-C}_4$ alkoxy;

Z is NH, NCH_3 , O, S, or CH_2 ;

Y is NH, O, or CH_2 with the proviso that Y and Z are not the same;

R_2 is H, halo, NH_2 , $\text{C}_1\text{-C}_4$ alkyl, hydroxy, or $\text{C}_1\text{-C}_4$ alkoxy;

m and n are independently selected from integers ranging from 1-5 with the proviso that $m + n =$ an integer ranging from 2-9; and

R_3 is H, halo, NH_2 , $\text{C}_1\text{-C}_4$ alkyl, hydroxy, or $\text{C}_1\text{-C}_4$ alkoxy;

or a pharmaceutically acceptable salt thereof.

Preferably, R_1 is hydroxy or $\text{C}_1\text{-C}_4$ alkoxy; Z is N or O; R_2 is H, halo, NH_2 or hydroxy; and R_3 is H.

The novel compounds of the present invention can be combined with standard pharmaceutically acceptable carriers or other known anti-tumor and chemotherapeutic agents.

Materials and Methods

Synthesis of TH-1177:

TH-1177 was synthesized in three simple steps as described (Haverstick,D.M., Heady,T.N., Macdonald,T.L., and Gray,L.S. 2000. Inhibition of human prostate cancer proliferation *in vitro* and in a mouse model by a compound synthesized to block Ca^{2+} entry. *Cancer Res* 60:1002-1008). L-Proline methyl ester

was coupled with 4-methoxyphenylacetic acid using benzotriazol-1-yl-oxytripyrrolidinephosphonium to generate methyl 1-[2-(4 methoxyphenyl)acetyl]pyrrolidine-2-carboxylate, a yellowish oil. The resulting amide was subsequently reduced to the amino alcohol with LiAlH_4 and AlCl_3 in tetrahydrofuran. The resulting colorless oil was coupled with 4-chlorobenzhydrol under Williamson conditions with catalytic p-toluenesulfonic acid in refluxing toluene. The final brownish oil was isolated by column chromatography, and its structure was confirmed by nuclear magnetic resonance and mass spectrometry. TH-1177 was dissolved in DMSO for use.

10

Cell Lines and Maintenance:

Cancer cell lines were obtained from the American Type Culture Collection (Manassas, VA). Cell lines were maintained in RPMI1640 supplemented with glutamine and 5% fetal bovine serum containing SerXtend (Irvine Scientific) when appropriate insulin, as directed by the ATCC. The fetal bovine serum used for culture was heat-inactivated by maintaining the serum at 56°C for 1 h. Cell lines used were a T cell leukemia (Jurkat), prostate cancer (PC3, DU145, LNCaP), breast cancer (MDA468, MDA361, MCF7), pancreatic cancer (MIA PaCa2), liver cancer (Hep G2), lung cancer (A549, NCI H460), colon cancer (HT29, HCT 116), and ovarian cancer (SK-OV-3).

20

Measurement of the $[\text{Ca}^{2+}]_i$ Concentration:

Cells were incubated in growth media containing 1 μM of the acetoxymethyl ester of the Ca^{2+} -sensitive fluorescent dye indo-1 (indo-1/AM; Molecular Probes, Eugene, OR) for 1 h at 37°C . Cells were washed three times in buffer A [10 mM HEPES (pH 7.4), 1 mM MgCl_2 , 3 mM KCl, 1 mM CaCl_2 , 140 mM NaCl, 0.1% glucose, and 1% fetal bovine serum] and suspended to a final concentration of 10^6 cells/ml. Before stimulation, cells were warmed to 37°C . Changes in $[\text{Ca}^{2+}]_i$ were monitored in an SLM 8100C spectrofluorometer (SLM/Aminco; Urbana, IL) using previously published methods

30

(Densmore,J.J., Haverstick,D.M., Szabo,G., and Gray,L.S. 1996. A voltage operable current is involved in activation-induced Ca^{2+} entry in human lymphocytes whereas I_{CRAC} has no apparent role. *Am.J.Physiol.* 271:C1494-C1503; Haverstick,D.M., Densmore,J.J., and Gray,L.S. 1998. Calmodulin regulation of Ca^{2+} entry in Jurkat T cells. *Cell Calcium* 23:361-368).

Measurement of Cellular Proliferation:

LNCaP cells at 2.5×10^4 cells/well or PC-3 cells at 5×10^4 cells/well, both in a final volume of 100 μL , were plated in triplicate in standard flat-bottomed 96-well tissue culture plates in the presence of drug or vehicle (DMSO). Unless otherwise indicated, cells were grown for 48 h at 37°C in a CO_2 incubator. Relative cell growth was determined with the CellTiter 96 aqueous cell proliferation assay (Promega, Madison, WI) as described by the manufacturer using an automated plate reader. Results were calculated in a blinded fashion and are the means of triplicate determinations.

Results

Construction of a novel chemical library:

Extracellular Ni^{2+} blocks the Ca^{2+} entry pathway in electrically non-excitable cells (Merritt,J.E., Jacob,R., and Hallam,T.J. 1989. Use of manganese to discriminate between calcium influx and mobilization from internal stores in stimulated human neutrophils. *J.Biol.Chem.* 264:1522-1527; Jones,G.R.N. 1985. Cancer therapy: Phenothiazines in an unexpected role. *Tumori* 71:563-569) as well as the current through T type Ca^{2+} channels (Lee,J.-H., Gomora,J.C., Cribbs,L.L., and Perez-Reyes,E. 2000. Nickel block of three cloned T-type Ca channels: low concentrations selectively block $\alpha_1\text{H}$. *Biophys.J.* 77:3042). We made use of these facts and conducted a search of the Medline database for compounds that block Ca^{2+} entry in any system that was also sensitive to inhibition of Ca^{2+} entry by Ni^{2+} . The identified compounds were then used as the basis for a reiterated search. This strategy was continued until the only citations returned were those that had been retrieved

already indicating that the database had been saturated. These agents, some of which are listed in Table 1, were tested for the ability to block proliferation of and Ca^{2+} entry into the Jurkat human cancer cell line. These compounds were tested in various cancer cell lines (Materials and Methods) with results similar to those obtained with the Jurkat cell line (data not shown). The correlation between these two inhibitory activities in the Jurkat cell line, expressed as IC_{50} 's, is shown in Figure 1, panel A. The resulting structure-activity relationship (SAR) was used as a guide to synthesize novel chemical agents. These novel compounds exhibited enhanced inhibition of Ca^{2+} entry and proliferation (Table 2). The slope of the regression line between the ability of the novel compounds to inhibit proliferation and block Ca^{2+} entry was 0.97 or very close to unity with an r^2 value of 0.93 (Figure 1, panel B) compared to a slope of 0.73 ($r^2 = 0.79$) for the known agents (Figure 1, panel A). Because Ca^{2+} entry is required for proliferation (Berridge, M.J., Lipp, P., and Bootman, M.D. 2000. The versatility and universality of calcium signalling. *Nat. Rev. Mol Cell Biol.* 1:11-21), the slope of 0.97 should most appropriately be interpreted in a Bayesian fashion. This Bayesian analysis suggests that all of the effect of these compounds on proliferation is mediated through inhibition of Ca^{2+} entry.

The Ca^{2+} ionophore ionomycin partially overcomes the effects of TH-1177. We have used one of our compounds, TH-1177, as the prototype for the others (Haverstick, D.M., Heady, T.N., Macdonald, T.L., and Gray, L.S. 2000. Inhibition of human prostate cancer proliferation *in vitro* and in a mouse model by a compound synthesized to block Ca^{2+} entry. *Cancer Res* 60:1002-1008). If TH-1177 is acting via inhibition of Ca^{2+} entry, its effects should be at least partially reversed by direct elevation of $[\text{Ca}^{2+}]_i$ using a Ca^{2+} ionophore. As shown in Figure 2, panel A, ionomycin overcame inhibition of Ca^{2+} entry by TH-1177 in a concentration dependent manner although there was no effect on proliferation of 30 nM ionomycin alone. Ionomycin also reduced the ability of TH-1177 to inhibit proliferation (Figure 2, panel B) increasing the IC_{50} of TH-1177 from 4.6 μM in the presence of 30 μM ionomycin to 17.8 μM in its absence. This suggests that TH-1177 is acting to inhibit

proliferation by inhibition of Ca²⁺ entry and is in accord with the relationship between Ca²⁺ entry and proliferation shown in Figure 1.

Cancer cell lines sensitive to our agents express message for the $\alpha 1H$ Ca²⁺ channel or its $\delta 25$ splice variant.

5 We have presented data previously suggesting that a member or members of the T type Ca²⁺ channel family have a role in mediating Ca²⁺ entry in electrically excitable cells (Densmore,J.J., Haverstick,D.M., Szabo,G., and Gray,L.S. 1996. A voltage operable current is involved in activation-induced Ca²⁺ entry in human lymphocytes whereas I_{CRAC} has no apparent role. *Am.J.Physiol.* 271:C1494-10 C1503; Densmore,J.J., Szabo,G., and Gray,L.S. 1992. A voltage-gated calcium channel is linked to the antigen receptor in Jurkat T lymphocytes. *FEBS Lett.* 312:161-164; Haverstick, D. M. and Gray, L. S. Increased intracellular Ca²⁺ induces Ca²⁺ influx in human T lymphocytes. *Molecular Biology of the Cell* 4, 173-184. 1993; Haverstick,D.M., Densmore,J.J., and Gray,L.S. 1998. Calmodulin regulation of Ca²⁺ 15 entry in Jurkat T cells. *Cell Calcium* 23:361-368). It has been shown recently that a prostate cancer line expresses the $\alpha 1H$ isoform of T type Ca²⁺ channels at levels that vary with differentiation status (Mariot,P., Vanoverberghe,K., Lalevee,N., Rossier,M.F., and Prevarskaya,N. 2002. Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer 20 cells. *J Biol.Chem* 277:10824-10833). Using the same primers, reported in that study, the value for TH-1211 is 24 uM. Thus, when measured by Ca²⁺ selective fluorescent dyes, Ca²⁺ entry was similarly sensitive to TH-1177 and TH-1211 as was the Ca²⁺ current mediated by $\alpha 1H$. As importantly, each of these measures of Ca²⁺ influx showed the same relative difference in sensitivity to the stereoisomers. This shows 25 the pharmacological correspondence between capacitative Ca²⁺ entry when measured by fluorescence and Ca²⁺ entry mediated by $\alpha 1H$ when measured by electrophysiological methods.

Discussion

Recently, several channels have been suggested as candidates for mediating Ca^{2+} entry in electrically non-excitable cells. A common feature of these proposed Ca^{2+} entry channels is that they are not voltage gated. This reflects the prevalent assumption that the Ca^{2+} entry pathways in electrically excitable and non-excitable cells are categorically distinct. It is extremely difficult, however, to understand why such an assumption is necessary particularly in view of the inherently non-categorical nature of biological systems. In addition, these voltage insensitive Ca^{2+} channels do not fulfill completely the biophysical criteria for the capacitative Ca^{2+} entry pathway in electrically non-excitable cells (Haverstick, D. M. and Gray, L. S. Increased intracellular Ca^{2+} induces Ca^{2+} influx in human T lymphocytes. *Molecular Biology of the Cell* 4, 173-184. 1993).

This uncertainty about the nature of Ca^{2+} entry in electrically non-excitable cells may be the result of a number of technical factors in addition to the constraints imposed by unnecessary assumption. While several of the proposed candidates for mediation of Ca^{2+} entry in electrically non-excitable cells have been characterized at the molecular level (Putney, J.W., Jr. and McKay, R.R. 1999. Capacitative calcium entry channels. *Bioessays* 21:38-46), a commonly accepted Candidate, I_{CRAC} (Clapham, D.E. 2002. Sorting out MIC, TRP, and CRAC Ion Channels. *J. Gen. Physiol* 120:217-220; Cahalan, M.D., Wulff, H., and Chandy, K.G. 2001. Molecular properties and physiological roles of ion channels in the immune system. *J Clin Immunol.* 21:235-252), has not. It is also difficult to tie the function of these channels to inhibition of proliferation of cancer cell lines because of the paucity of specific Ca^{2+} entry inhibitors for electrically non-excitable cells. There is as well the unavoidable disjunction between Ca^{2+} entry as measured by Ca^{2+} selective fluorescent dyes and electrophysiological methods: The patch-clamp technique is extraordinarily powerful for examining the biophysical details of the function of an ion channel (Neher, E. and Sakmann, B. 1992. The patch clamp technique. *Scientific American* March:44-51), however the level of membrane control it both achieves and requires makes it less suited to identifying a channel's physiological role. Fluorescence

techniques are very limited in obtaining biophysical detail but better able to study physiological roles. This disconnection makes it difficult to determine if the effects of physiologically relevant stimuli, as determined by fluorescence measurements, are reproduced at the electrophysiological level.

5 We have suggested that the mechanism of Ca^{2+} entry in electrically non-excitable cells involves a Ca^{2+} channel sharing characteristics with the T type family of voltage gated Ca^{2+} channels (Densmore,J.J., Haverstick,D.M., Szabo,G., and Gray,L.S. 1996. A voltage operable current is involved in activation-induced Ca^{2+} entry in human lymphocytes whereas I_{CRAC} has no apparent role. *Am.J.Physiol.* 271:C1494-C1503; Densmore,J.J., Szabo,G., and Gray,L.S. 1992. A voltage-gated calcium channel is linked to the antigen receptor in Jurkat T lymphocytes. *FEBS Lett.* 312:161-164; Haverstick, D. M. and Gray, L. S. Increased intracellular Ca^{2+} induces Ca^{2+} influx in human T lymphocytes. *Molecular Biology of the Cell* 4, 173-184. 1993; Haverstick,D.M., Densmore,J.J., and Gray,L.S. 1998. Calmodulin regulation of Ca^{2+} entry in Jurkat T cells. *Cell Calcium* 23:361-368). It could be argued that it is difficult to envision a physiologic role for voltage gated Ca^{2+} channels in cells that do not have action potentials. This argument is, however, based upon the assumption that a voltage gated Ca^{2+} channel can be only be activated by an action potential. Such an assumption is false *a priori* because the means by which a protein can be regulated by imposed experimental conditions is not necessarily identical with, or even similar to, the mechanism by which it is controlled physiologically. Although secondary to regulation by membrane potential, the known biochemical regulation of voltage gated Ca^{2+} channels in a variety of systems also suggests that the categorical distinction between electrical and biochemical regulation of Ca^{2+} channels may be simplistic.

25 The data presented here strongly suggest the possibility that the $\alpha 1\text{H}$ isoform of nominally voltage gated T type Ca^{2+} channels or its 825 splice variant has a role in Ca^{2+} entry into and proliferation of electrically non-excitable cancer cells. Our data show that novel compounds can be created based upon an structure-activity relationship generated from compounds that are known to inhibit Ca^{2+} entry in
30 systems that are also sensitive to inhibition by Ni^{2+} . These novel compounds also

inhibit proliferation of several cancer cell lines via blockade of Ca²⁺ entry. The cell lines that are sensitive to our agents express message for $\alpha 1H$ Ca²⁺ channels, its $\delta 25$ splice variant, or both. These compounds also inhibit the Ca²⁺ current mediated by $\alpha 1H$ Ca²⁺ channels and slow the proliferation of HEK293 cells stably transfected with the $\alpha 1H$ Ca²⁺ channel isoform. TH-1177 and TH-1211 stereoselectively inhibit Ca²⁺ entry into and proliferation of cancer cell lines and show the same-stereoselectivity and potency in blocking canonical $\alpha 1H$. These data strongly suggest that the $\alpha 1H$ Ca²⁺ channel and its $\delta 25$ splice variant participate in Ca²⁺ entry in the cancer cell lines tested in these studies.

Linking biophysical analysis of Ca²⁺ channel function to a physiological function such as proliferation can pose challenges. We have demonstrated that our compounds block a heterologously expressed Ca²⁺ channel and that only those cancer cell lines with message for that channel, or its splice variant, are sensitive to inhibition by the same agents. Furthermore, TH-1177 is more potent at inhibiting Ca²⁺ entry via expressed $\alpha 1H$ as measured by biophysical techniques than the stereoisomer of it, TH-1211. TH-1177 and TH-1211 also show the same rank order of potency at inhibiting proliferation and Ca²⁺ entry in cancer cell lines when these are assayed by more commonly used biochemical methods. The absolute potencies of the agents as measured by IC₅₀ values are strikingly similar whether measured by biophysical or biochemical methods. Thus, the results from a combination of experimental approaches were synthesized into a picture of the likely mechanism of Ca²⁺ entry in some cancer cells.

Expression of the $\alpha 1H$ Ca²⁺ channel has been demonstrated in LNCaP cells and the expression level correlates with differentiation state (Mariot, P., Vanoverberghe, K., Lalevee, N., Rossier, M.F., and Prevarskaya, N. 2002. Overexpression of an $\alpha 1H$ (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. *J Biol. Chem* 277:10824-10833). Although the sequence of the $\delta 25$ splice variant has been deposited in GenBank (accession number AF223563), its function has not been described to our knowledge. However, both are members of the T type Ca²⁺ channel

family by sequence homology and have been assigned to the Hs.122359 UniGene cluster within the NCBI database. The physiological roles of T type Ca^{2+} channels are not wholly clear at present although they may play a role as pacemakers in the heart and central nervous system (Chemin,J., Monteil,A., Perez-Reyes,E., Bourinet,E., Nargeot,J., and Lory,P. 2002. Specific contribution of human T-type calcium channel isotypes (α_{1G} , α_{1H} and α_{1I}) to neuronal excitability. *J.Physiol.(Lond.)* 540:3-14; McDonald,T.F., Pelzer,S., Trautwein,W., and Pelzer,D.J. 1994. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. *Physiol Rev* 74:365-507). The expression of these Ca^{2+} channels also appears to be developmentally regulated (Brooks,G., Harper,J.V., Bates,S.E., Haworth,R.S., Cribbs,L.L., Perez-Reyes,E., and Shattock,M.J. 1999. Over expression of the voltage-gated T-type calcium channel induces vascular smooth muscle cell proliferation. *Circulation* 100:I-209(Abstr.); Clozel,J.P., Ertel,E.A., and Ertel,S.I. 1999. Voltage-gated T-type Ca^{2+} channels and heart failure. *Proc.Assoc.Am Physicians* 111:429-437; Harper,J.V., McLatchie,L., Perez-Reyes,E., Cribbs,L.L., Shattock,M.J., and Brooks,G. 2000. T-type calcium channel expression is necessary for G1-S progression in vascular smooth muscle. *Circulation* 102:II-48 (Abstr.); Monteil,A., Chemin,J., Bourinet,E., Mennessier,G., Lory,P., and Nargeot,J. 2000. Molecular and functional properties of the human α_{1G} subunit that forms T-type calcium channels. *J Biol.Chem.* 275:6090-6100) and the data reported here suggest that both canonical α_{1H} and its $\delta 25$ splice variant are responsible for the Ca^{2+} entry required for proliferation of some cancer cell lines. These data are also consistent with the idea that the so-called voltage gated Ca^{2+} channels are likely to have a physiological role in cell types conventionally categorized as electrically non-excitable.


Our novel synthetic compounds may have clinical utility because treatment of mice bearing xenografted human PC3 prostate cancer cells with TH-1177 significantly extended the lifespan of them (Haverstick,D.M., Heady,T.N., Macdonald,T.L., and Gray,L.S. 2000. Inhibition of human prostate cancer proliferation *in vitro* and in a mouse model by a compound synthesized to block Ca^{2+} entry. *Cancer Res* 60:1002-1008). Thus, it is possible that Ca^{2+} channel inhibitors

will ultimately provide clinicians with an addition to their armamentarium for the treatment of cancer. The observations presented here, as well as those presented previously (Haverstick,D.M., Heady,T.N., Macdonald,T.L., and Gray,L.S. 2000. Inhibition of human prostate cancer proliferation *in vitro* and in a mouse model by a
5 compound synthesized to block Ca^{2+} entry. *Cancer Res* 60:1002-1008), lay the groundwork for further developments in this area.

WHAT IS CLAIMED IS:

1. A method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises
 5 administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug.

2. The method according to claim 1, wherein the T type calcium channel
 10 inhibitor has a structure represented by Formula (I):



Formula(I),

wherein

R₁ is C₁-C₄ alkyl, hydroxy, or C₁-C₄ alkoxy;

Z is NH, NCH₃, O, S, or CH₂;

15 Y is NH, O, or CH₂ with the proviso that Y and Z are not the same;

R₂ is H, halo, NH₂, C₁-C₄ alkyl, hydroxy, or C₁-C₄ alkoxy;

m and n are independently selected from integers ranging from 1-5 with the
 proviso that m + n = an integer ranging from 2-9; and

R₃ is H, halo, NH₂, C₁-C₄ alkyl, hydroxy, or C₁-C₄ alkoxy.

20

3. The method according to claim 2, wherein R₁ is hydroxy or C₁-C₄ alkoxy; Z is
 N or O; R₂ is H, halo, NH₂ or hydroxy; and R₃ is H.


25

4. The method according to claim 1, wherein the disease or condition is selected from the group consisting of unstable angina, hypertension, epilepsy, neuropathic pain, petit mal seizure, absence seizure, age related macular degeneration, cancer, and pre-cancerous condition.

5

5. A method for reducing proliferation of electrically non-excitable cells, which comprises administering a T type calcium channel inhibitor as described in claim 2.

6. A compound of Formula (I)



Formula(I),

10

wherein

R_1 is C_1 - C_4 alkyl, hydroxy, or C_1 - C_4 alkoxy;

Z is NH, NCH₃, O, S, or CH₂;

Y is NH, O, or CH₂ with the proviso that Y and Z are not the same;

15

R_2 is H, halo, NH₂, C_1 - C_4 alkyl, hydroxy, or C_1 - C_4 alkoxy;

m and n are independently selected from integers ranging from 1-5 with the proviso that $m + n =$ an integer ranging from 2-9; and

R_3 is H, halo, NH₂, C_1 - C_4 alkyl, hydroxy, or C_1 - C_4 alkoxy;


or a pharmaceutically acceptable salt thereof.

20

7. The compound according to claim 6, wherein R_1 is hydroxy or C_1 - C_4 alkoxy; Z is N or O; R_2 is H, halo, NH₂ or hydroxy; and R_3 is H.

25

8. The compound according to claim 6, is selected from the group consisting of the following compounds:



9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as described in claim 6, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.

10. A method for the treatment of cancer or pre-cancerous condition in a mammal, which comprises administering to the mammal a therapeutically effective amount of a compound of formula (I) as described in claim 6 a prodrug thereof, or a

pharmaceutically acceptable salt of said compound or prodrug in combination with one or more anti-tumor agent.

11. A pharmaceutical combination composition comprising a therapeutically
5 effective amount of a combination of a compound of formula (I) as described in claim 6, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug; and one or more anti-tumor agent.

10

FIGURE 1




FIGURE 2





FIGURE 3

FIGURE 4**Jurkat forward alignment**

```
1      ctcttgggggtaggcatgggcgtggcagctgtgcacatgatgaggggaggggacaggctg 60
      |||
3348 ctcttgggggtaggcatgggcgtggcagctgtgcacatgatgaggggaggggacaggctg 3289

61      cctcgtccctccagggtgccggtgggggtcacggccagggaacacatcttcagctctgt 120
      |||
3288 cctcgtccctccagggtgccggtgggggtcacggccagggaacacatcttcagctctgt 3230

121     ggtctggagttctctgagcttgtggaagtcctcctcgaag 160
      |||
3229 ggtctggagttctctgagcttgtggaagtcctcctcgaag 3190
```

SK-N-SH forward alignment

```
21      cagggtgcgtgtggtcgggtgggtgggtccgggttctggcgggtggagtagcgtgggctggcc 80
      |||
3507 cagggtgcgtgtggtcgggtgggtgggtccgggttctggcgggtggagtagcgtgggctggcc 3566

81      gggcagggcccccataaggcaatccctaggttgggggattcctggtcctgggagcctggc 140
      |||
3567 gggcagggcccccataaggcaatccctaggttgggggattcctggtcctgggagcctggc 3626

141     agctctaggggcccattcctccctctgtcccgcagagctnaagatgtgttccctggccgt 200
      |||
3627 agctctaggggcccattcctccctctgtcccgcagagctgaagatgtgttccctggccgt 3686

201     ncccccaacggggcacctggagggacnaggcagcctgtcccntcccntnatnatgtgcac 260
      |||
3687 gcccccaacggggcacctggagggacnaggcagcctgtcccntcccntcatcatgtgcac 3746

261     agntgccacgcccattgctacccccaanagctcacnttcttgg 304
      ||
3747 agntgccacgcccattgctacccccaanagctcacnttcttgg 3790
```

FIGURE 5

Does inhibition of proliferation
correlate with block of canonical
 $\alpha 1H$?





FIGURE 6

A



B




FIGURE 7




Table 1

Drug	IC ₅₀ for inhibition of proliferation	IC ₅₀ for inhibition of Ca ²⁺ entry
Bepriidil	10	5
Bupropion	>100	>100
Chlorcyclizine	90	25
Cinnarizine	30	30
Clozapine	>100	>100
Ethopropazine	30	10
Fendiline	30	10
Flunarizine	30	5
Fluphenazine	10	10
Isradipine	100	10
Lidoflazine	10	5
Meclizine	30	30
Methotrimeprazine	30	10
NDGA*	30	10
Nicardipine	30	10
Niflumic acid	100	50
Nimodipine	>100	>100
Perhexiline	10	5
Pimozide	>100	>100
Prenylamine lactate	10	10
Prochlorperazine	3	10
Promazine	30	10
Promethazine	4	60
Propiomazine	30	30
Tetrandrine	3	10


*Nordihydroguaiaretic acid

Table 2

Drug	IC ₅₀ for inhibition of proliferation	IC ₅₀ for inhibition of Ca ²⁺ entry
11087	8.3	20
11096	5	3
11113	13	10
11177	6	7
11203	13.8	8
11205	8.8	10
11211	8.6	15
12019	3.6	5
12029	8.4	7
12043	11	10
12083	11	12
12085	8	10
12129	13	15
12149	100	100
12151	11	3
12153	10	3
12210	40	30
12179	10	10
13028	12	3
13029	5	7
13101	5	5
13104	4	1
13105	5	3
13186	13	3
13284	60	30
14099	108	100
21052	50	7
21064	100	100
21070	100	100
21092	50	30
21104	30	30
23015	30	30

Table 3

Cell Type	Cell Line	RT-PCR Product
T-cell	Jurkat	α 1H
Prostate	PC-3	δ 25 variant/ α 1H
	DU-145	α 1H
Breast	MDA-231	δ 25 variant
	MDA-361	δ 25 variant
	MDA-435	δ 25 variant/ α 1H
Neuroblastoma	SK-N-SH	δ 25 variant



(I)